New Medicines
Brolucizumab is an additional anti-VEGF agent for treating wAMD, to sit alongside ranibizumab and aflibercept in the treatment pathway. PBR excluded high cost drug, for specialist use only.
Not recommended until NICE TA published.
Not recommended until NICE TA published.
Not recommended until NICE TA published.
Formulary and Guidelines
Addition of oral formulation to formulary. Cost neutral in comparison with injectable formulation.
Update of current statement at review-by date – minor changes regarding specialist to specify garment size.
Safety
This document brings together a number of resources clinicians can use to support the appropriate use and review of opioids used for chronic pain.
Antimicrobials
The final part now complete. All chapters are available on the APC website. CCG medicines management teams are requested to circulate this information to prescribers.
|